1
|
Yang Y, Wang J, Wanasathop A, Niu M, Ghosh P, Zidan A, Gu J, Hunt R, Faustino P, Ashraf M, Xu X. Evaluation of in vitro Skin Permeation of Clascoterone From Clascoterone Topical Cream, 1% (w/w). AAPS PharmSciTech 2024; 25:186. [PMID: 39138712 DOI: 10.1208/s12249-024-02887-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Accepted: 07/07/2024] [Indexed: 08/15/2024] Open
Abstract
Winlevi® (clascoterone) topical cream (1%, w/w) was approved by the U.S. FDA for the treatment of acne vulgaris in patients 12 years of age and older. The active ingredient, clascoterone, is not stable in physiological solutions and can hydrolyze to cortexolone at body temperature. Instability of clascoterone poses a significant challenge in accurately assessing the rate and extent of clascoterone permeation in vitro. Therefore, the purpose of this study was to develop an in vitro skin permeation test (IVPT) method, and a robust analytical method, that can minimize hydrolyzation of clascoterone during the study for quantification of clascoterone. Two IVPT methods, using either vertical diffusion cells or flow-through cells, were developed and compared to evaluate in vitro permeation of clascoterone from Winlevi. A liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was developed to monitor the level of clascoterone and cortexolone in the IVPT samples. The analytical method features a 2-min high-throughput analysis with good linearity, selectivity, and showed a lower limit of quantitation (LLOQ) of 0.5 ng/mL for both clascoterone and cortexolone. The in vitro skin permeation of clascoterone and cortexolone was observed as early as 2 h in both IVPT methods. A substantive amount of clascoterone was found to hydrolyze to cortexolone when using the vertical static diffusion cells with aliquot sampling. Conversely, degradation of clascoterone was significantly minimized when using the flow-through diffusion cells with fractional sampling. The data enhanced our understanding of in vitro permeation of clascoterone following topical application of the Winlevi topical cream, 1% and underscores the importance of IVPT method development and optimization during product development.
Collapse
Affiliation(s)
- Yang Yang
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA.
| | - Jiang Wang
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
- Division of Bioequivalence III, Office of Bioequivalence, Office of Generic Drugs, CDER, U.S. FDA, Silver Spring, MD, USA
| | - Apipa Wanasathop
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Mengmeng Niu
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, CDER, U.S. FDA, Silver Spring, MD, USA
| | - Priyanka Ghosh
- Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, CDER, U.S. FDA, Silver Spring, MD, USA
| | - Ahmed Zidan
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Jianghong Gu
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Robert Hunt
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Patrick Faustino
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Muhammad Ashraf
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| | - Xiaoming Xu
- Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA
| |
Collapse
|
2
|
Pa HP, S G P, K P, Murthy SN, Murthy PN, Wali D, Kumar A, Matadh AV, H N S, Murthy SN. BIOPHYSICAL AND PERMEABILITY CHARACTERIZATION OF LYOPHILIZED (FREEZE-DRIED) HUMAN CADAVER SKIN. Eur J Pharm Sci 2024:106870. [PMID: 39102996 DOI: 10.1016/j.ejps.2024.106870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Revised: 07/10/2024] [Accepted: 08/03/2024] [Indexed: 08/07/2024]
Abstract
The in vitro permeation testing (IVPT) of topical products is performed across the human cadaver skin, which is stored frozen for a prolonged duration. The cryo-preservation technique is not economical and is a cumbersome process. Moreover, prolonged skin preservation in a frozen state and frequent freeze-thawing are known to affect the integrity of the skin barrier. Therefore, lyophilization was explored as an alternative to protect the skin tissue from microbial contamination and degeneration. Notably, the project's objective was to investigate the impact of the freeze-drying process on the skin's barrier properties. The morphometrics of the lyophilized skin were measured. Histological studies did not reveal any notable changes in the organization and intactness of the layers due to the freeze-drying process. The biophysical attributes of the skin, such as transepidermal water evaporation rate and transepidermal electrical resistivity (TEER), were not significantly different between the control skin (not subjected to the freeze-drying process) and the freeze-dried skin (FDS). The permeability of caffeine, a hydrophilic model permeant, and nicotine, a lipophilic model permeant, were consistent across the control and the FDS. It is evident from the studies that the lyophilization process did not significantly impact the barrier properties and permeability of the skin.
Collapse
Affiliation(s)
- Harini Priya Pa
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Pragathi S G
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Poornima K
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Srujana N Murthy
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Prajwal N Murthy
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Divya Wali
- KLE College of Pharmacy, Bangalore, India
| | | | - Anusha V Matadh
- Institute for Drug Delivery and Biomedical Research, Bangalore, India
| | - Shivakumar H N
- Institute for Drug Delivery and Biomedical Research, Bangalore, India; KLE College of Pharmacy, Bangalore, India
| | - S Narasimha Murthy
- Institute for Drug Delivery and Biomedical Research, Bangalore, India; Topical Product Testing LLC, MS, USA.
| |
Collapse
|
3
|
Shelke O, Susarla KPC, Bankar M. Understand the Stabilization Engineering of Ascorbic Acid, Mapping the Scheme for Stabilization, and Advancement. AAPS PharmSciTech 2024; 25:159. [PMID: 38987438 DOI: 10.1208/s12249-024-02882-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 06/30/2024] [Indexed: 07/12/2024] Open
Abstract
Vitamin C is extensively used in cosmetic formulation, howbeit stability is the supreme demerit that limits its use in beautifying products. Numerous techniques are being employed to inhibit the degradation of vitamin C caused by formulation components to facilitate the use in skin rejuvenating products. Diverse materials are being exercised in formulation to stabilize the ascorbic acid and ingredients selected in this formulation composition help for stabilization. The initial stable prototype is developed and further optimization is accomplished by applying the design of experiment tools. The stable pharmaceutical formulations were evaluated for the evaluation parameters and designated as two optimized formulations. The analytical method for the assay of ascorbic acid from the United States pharmacopeia and the related substance method from European pharmacopeia has been modified to be used for cream formulation. The DoE design exhibited that the stability of formulation is impacted by citric acid and tartaric acid but not by propylene glycol and glycerin. The analysis results of topical formulations for the evaluation parameter exhibited satisfactory results. The in-vitro release study method has been developed, optimized, and validated to fit the analysis. The in-vitro studies have been performed for selected compositions and both the formulation has similar kinds of release patterns. The stability study as per ICH guidelines exhibited that the product is stable for accelerated, intermediate, and room-temperature storage conditions. The optimized formulation shows constant release and permeation of ascorbic acid through the skin. The formulation with the combinations of citric acid, tartaric acid, and tocopherol is more stable and the degradation of vitamin C has been reduced significantly. The beaucoup strategies in the unique composition help to protect the degradation by inhibiting the multitudinous degradation pathways.
Collapse
Affiliation(s)
- Om Shelke
- Department of Pharmaceutics, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India.
- Formulation and Development, Sinomune Pharmaceutical Co. Ltd., Wuxi, China.
| | | | - Manish Bankar
- Department of Pharmaceutics, Shri Veerbhadreshwar Education Trust's College of Pharmacy, Humnabad, Karnataka, India
| |
Collapse
|
4
|
Sarnthiratch M, Alsheddi L, Nimmansophon P, Wanasathop A, Li SK. Effect of Receptor Solution in Studies of In Vitro Permeation Test (IVPT). J Pharm Sci 2024; 113:407-418. [PMID: 37972891 DOI: 10.1016/j.xphs.2023.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 11/08/2023] [Accepted: 11/08/2023] [Indexed: 11/19/2023]
Abstract
In Vitro Permeation Test (IVPT) is commonly used to evaluate skin penetration of chemicals and performance of dermatological products. For a permeant with low aqueous solubility, an additive that is expected not to alter the skin barrier can be used in the receptor solution to improve permeant solubility. The objective of this study was to (a) evaluate the effects of these additives in IVPT receptor solution on skin permeability of model permeants and skin electrical resistance and (b) determine the solubility of the permeants in these receptor solutions. Bovine serum albumin (BSA), 2-hydroxypropyl-beta-cyclodextrin (HPCD), ethanol, nonionic surfactant Brij-98, and propylene glycol were the additives, and phosphate buffered saline (PBS) was the control. Steady-state skin permeability coefficients and resistances were determined. The receptor solutions examined in this study did not cause a significant increase in skin permeability or decrease in resistance (less than 40 % changes) except 25 % ethanol. The receptor solution containing 25 % ethanol induced an approximately twofold average increase in skin permeability and reduced skin electrical resistance by approximately threefold. The receptor solution of 2.5 % HPCD provided the highest levels of solubility for the model lipophilic permeants, while 0.2 % Brij-98 and 5 % ethanol showed the lowest solubility enhancement from those in PBS.
Collapse
Affiliation(s)
- Minthira Sarnthiratch
- Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - Lama Alsheddi
- Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - Patcharawan Nimmansophon
- Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - Apipa Wanasathop
- Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - S Kevin Li
- Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States.
| |
Collapse
|
5
|
Salminen AT, Manga P, Camacho L. Race, pigmentation, and the human skin barrier-considerations for dermal absorption studies. FRONTIERS IN TOXICOLOGY 2023; 5:1271833. [PMID: 37886124 PMCID: PMC10598584 DOI: 10.3389/ftox.2023.1271833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 09/22/2023] [Indexed: 10/28/2023] Open
Abstract
A functional human skin barrier is critical in limiting harmful exposure to environmental agents and regulating the absorption of intentionally applied topical drug and cosmetic products. Inherent differences in the skin barrier between consumers due to extrinsic and intrinsic factors are an important consideration in the safety assessment of dermatological products. Race is a concept often used to describe a group of people who share distinct physical characteristics. The observed predisposition of specific racial groups to certain skin pathologies highlights the potential differences in skin physiology between these groups. In the context of the human skin barrier, however, the current data correlating function to race often conflict, likely as a consequence of the range of experimental approaches and controls used in the existing works. To date, a variety of methods have been developed for evaluating compound permeation through the human skin, both in vivo and in vitro. Additionally, great strides have been made in the development of reconstructed human pigmented skin models, with the flexibility to incorporate melanocytes from donors of different race and pigmentation levels. Together, the advances in the production of reconstructed human skin models and the increased adoption of in vitro methodologies show potential to aid in the standardization of dermal absorption studies for discerning racial- and skin pigmentation-dependent differences in the human skin barrier. This review analyzes the existing data on skin permeation, focusing on its interaction with race and skin pigmentation, and highlights the tools and research opportunities to better represent the diversity of the human populations in dermal absorption assessments.
Collapse
Affiliation(s)
- Alec T Salminen
- U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, AR, United States
| | - Prashiela Manga
- U.S. Food and Drug Administration, Office of Cosmetics and Colors, Center for Food Safety and Applied Nutrition, College Park, MD, United States
| | - Luísa Camacho
- U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, AR, United States
| |
Collapse
|
6
|
Salminen AT, Davis KJ, Felton RP, Nischal N, VonTungeln LS, Beland FA, Derr K, Brown PC, Ferrer M, Katz LM, Kleinstreuer NC, Leshin J, Manga P, Sadrieh N, Xia M, Fitzpatrick SC, Camacho L. Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitro. Toxicol In Vitro 2023; 91:105630. [PMID: 37315744 PMCID: PMC10527924 DOI: 10.1016/j.tiv.2023.105630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 05/24/2023] [Accepted: 06/09/2023] [Indexed: 06/16/2023]
Abstract
Skin permeation is a primary consideration in the safety assessment of cosmetic ingredients, topical drugs, and human users handling veterinary medicinal products. While excised human skin (EHS) remains the 'gold standard' for in vitro permeation testing (IVPT) studies, unreliable supply and high cost motivate the search for alternative skin barrier models. In this study, a standardized dermal absorption testing protocol was developed to evaluate the suitability of alternative skin barrier models to predict skin absorption in humans. Under this protocol, side-by-side assessments of a commercially available reconstructed human epidermis (RhE) model (EpiDerm-200-X, MatTek), a synthetic barrier membrane (Strat-M, Sigma-Aldrich), and EHS were performed. The skin barrier models were mounted on Franz diffusion cells and the permeation of caffeine, salicylic acid, and testosterone was quantified. Transepidermal water loss (TEWL) and histology of the biological models were also compared. EpiDerm-200-X exhibited native human epidermis-like morphology, including a characteristic stratum corneum, but had an elevated TEWL as compared to EHS. The mean 6 h cumulative permeation of a finite dose (6 nmol/cm2) of caffeine and testosterone was highest in EpiDerm-200-X, followed by EHS and Strat-M. Salicylic acid permeated most in EHS, followed by EpiDerm-200-X and Strat-M. Overall, evaluating novel alternative skin barrier models in the manner outlined herein has the potential to reduce the time from basic science discovery to regulatory impact.
Collapse
Affiliation(s)
- Alec T Salminen
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA
| | - Kelly J Davis
- Toxicologic Pathology Associates, Jefferson, AR, USA
| | - Robert P Felton
- Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA
| | - Nathania Nischal
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA
| | - Linda S VonTungeln
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA
| | - Frederick A Beland
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA
| | - Kristy Derr
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Paul C Brown
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Marc Ferrer
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Linda M Katz
- Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD, USA
| | - Nicole C Kleinstreuer
- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Jonathan Leshin
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Rockville, MD, USA
| | - Prashiela Manga
- Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD, USA
| | - Nakissa Sadrieh
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Menghang Xia
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Suzanne C Fitzpatrick
- Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD, USA
| | - Luísa Camacho
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
| |
Collapse
|
7
|
Nimmansophon P, Wanasathop A, Li SK. Lateral Transport During Membrane Permeation in Diffusion Cell: In Silico Study on Edge Effect and Membrane Blocking. J Pharm Sci 2023; 112:1653-1663. [PMID: 36731779 PMCID: PMC10192071 DOI: 10.1016/j.xphs.2023.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 01/23/2023] [Accepted: 01/24/2023] [Indexed: 02/01/2023]
Abstract
Membrane transport in diffusion cell studies is not one-dimensional from the donor to the receptor. Lateral diffusion within the membrane into the surrounding clamped region can lead to edge effect. Lateral diffusion can also affect the impact of an object blocking the membrane in a diffusion cell. The effects of lateral transport on permeation across a two-layer membrane in diffusion cells were investigated in this study under edge effect and membrane blocking conditions that could be encountered in previous gingiva and hypothetical skin permeation studies. Model simulations of time-dependent and steady-state transport were performed using COMSOL Multiphysics. The simulations indicated edge effect could increase the steady-state flux across the membrane up to 35% with a relatively thick membrane and small diffusion cell opening (e.g., gingiva study). The edge effect decreased when the relative thickness and permeability of the major barrier (top layer in the two-layer membrane) decreased. When the membrane was partially blocked by an object, lateral diffusion within the membrane could mitigate its impact: e.g., when the object was in the receptor, the impact caused by membrane blocking was reduced more than half. Therefore, membrane lateral transport should be considered under certain circumstances in permeation studies using diffusion cells.
Collapse
Affiliation(s)
- Patcharawan Nimmansophon
- Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - Apipa Wanasathop
- Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States
| | - S Kevin Li
- Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States.
| |
Collapse
|
8
|
D'Ruiz CD, Plautz JR, Schuetz R, Sanabria C, Hammonds J, Erato C, Klock J, Vollhardt J, Mesaros S. Preliminary clinical pharmacokinetic evaluation of bemotrizinol - A new sunscreen active ingredient being considered for inclusion under FDA's over-the-counter (OTC) sunscreen monograph. Regul Toxicol Pharmacol 2023; 139:105344. [PMID: 36738872 DOI: 10.1016/j.yrtph.2023.105344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 01/20/2023] [Accepted: 01/28/2023] [Indexed: 02/05/2023]
Abstract
Protection against sunburn, skin damage and the carcinogenic effects of ultraviolet light are the primary health benefits associated with UV filters used in topical sunscreen drug products. Countries such as Europe have 30+ UV filters approved for sunscreen products while the US has about 10, greatly reducing the options to provide diverse, effective sun protection products. Bemotrizinol (BEMT) is the first new sunscreen active ingredient to be evaluated for inclusion in the Over-The-Counter (OTC) sunscreen monograph using FDA's new Generally Recognized as Safe and Effective (GRASE) testing guidelines. An in vitro skin permeation test (IVPT) and clinical pilot pharmacokinetic Maximum Usage Trial (MUsT) were completed to support the GRASE determination for 6% BEMT. IVPT results indicated an oil +10% ethanol as the model sunscreen intervention for the pilot MUsT. The open-label trial revealed: BEMT concentrations rarely exceeded FDA's defined threshold (0.5 ng/mL) in plasma; no evidence for BEMT accumulation or steady-state concentrations above threshold; only one moderate and few mild treatment emergent adverse events (TEAEs). Therefore, maximal topical applications of 6% BEMT in a model sunscreen formulation did not contribute to meaningful systemic exposure. These results support the safety of BEMT 6% for human sunscreen use.
Collapse
Affiliation(s)
- Carl D D'Ruiz
- DSM Nutritional Products LLC, 45 Waterview Boulevard, Parsippany, NJ, 07054-1298, USA.
| | - James R Plautz
- CHRYSALIS Services AG, Baeumleingasse 10, 4051, Basel, Switzerland
| | - Rolf Schuetz
- DSM Nutritional Products AG, Wurmisweg 576, 4303, Kaiseraugst, Switzerland
| | - Carlos Sanabria
- Spaulding Clinical Research, 525 S. Silverbrook Drive, West Bend, WI, USA
| | - Jody Hammonds
- Spaulding Clinical Research, 525 S. Silverbrook Drive, West Bend, WI, USA
| | - Cassandra Erato
- Spaulding Clinical Research, 525 S. Silverbrook Drive, West Bend, WI, USA
| | - Jochen Klock
- DSM Nutritional Products AG, Wurmisweg 576, 4303, Kaiseraugst, Switzerland
| | - Juergen Vollhardt
- DSM Nutritional Products AG, Wurmisweg 576, 4303, Kaiseraugst, Switzerland
| | - Szilvia Mesaros
- DSM Nutritional Products AG, Wurmisweg 576, 4303, Kaiseraugst, Switzerland
| |
Collapse
|
9
|
Topical Semisolid Products-Understanding the Impact of Metamorphosis on Skin Penetration and Physicochemical Properties. Pharmaceutics 2022; 14:pharmaceutics14112487. [PMID: 36432678 PMCID: PMC9692522 DOI: 10.3390/pharmaceutics14112487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/14/2022] [Accepted: 11/15/2022] [Indexed: 11/19/2022] Open
Abstract
Recently, the United States Food and Drug Administration published a series of product-specific guidance for the development of topical drugs, with in vitro options consisting of qualitative sameness (Q1) and quantitative sameness (Q2) assessment of formulations, physiochemical and structural characterization of formulations (Q3), and, potentially, in vitro drug release and permeation tests. In these tests, the topical semisolid product's critical quality attributes (CQAs), such as rheological properties, thermodynamic activity, particle size, globule size, and rate/extent of drug release/permeation, are evaluated to ensure the desired product quality. However, alterations in these CQAs of the drug products may occur under 'in use' conditions because of various metamorphosis events, such as evaporation that leads to supersaturation and crystallization, which may eventually result in specific failure modes of semisolid products. Under 'in use' conditions, a limited amount of formulation is applied to the skin, where physicochemical characteristics of the formulation are substantially altered from primary state to secondary and, eventually, tertiary state on the skin. There is an urgent need to understand the behavior of topical semisolid products under 'in use' conditions. In this review, we attempt to cover a series of metamorphosis events and their impact on CQAs (Q3 attributes), such as viscosity, drug activity, particle size, globule size, and drug release/permeation of topical semisolid products.
Collapse
|
10
|
Najjar A, Punt A, Wambaugh J, Paini A, Ellison C, Fragki S, Bianchi E, Zhang F, Westerhout J, Mueller D, Li H, Shi Q, Gant TW, Botham P, Bars R, Piersma A, van Ravenzwaay B, Kramer NI. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. Arch Toxicol 2022; 96:3407-3419. [PMID: 36063173 PMCID: PMC9584981 DOI: 10.1007/s00204-022-03356-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 08/03/2022] [Indexed: 11/28/2022]
Abstract
With an increasing need to incorporate new approach methodologies (NAMs) in chemical risk assessment and the concomitant need to phase out animal testing, the interpretation of in vitro assay readouts for quantitative hazard characterisation becomes more important. Physiologically based kinetic (PBK) models, which simulate the fate of chemicals in tissues of the body, play an essential role in extrapolating in vitro effect concentrations to in vivo bioequivalent exposures. As PBK-based testing approaches evolve, it will become essential to standardise PBK modelling approaches towards a consensus approach that can be used in quantitative in vitro-to-in vivo extrapolation (QIVIVE) studies for regulatory chemical risk assessment based on in vitro assays. Based on results of an ECETOC expert workshop, steps are recommended that can improve regulatory adoption: (1) define context and implementation, taking into consideration model complexity for building fit-for-purpose PBK models, (2) harmonise physiological input parameters and their distribution and define criteria for quality chemical-specific parameters, especially in the absence of in vivo data, (3) apply Good Modelling Practices (GMP) to achieve transparency and design a stepwise approach for PBK model development for risk assessors, (4) evaluate model predictions using alternatives to in vivo PK data including read-across approaches, (5) use case studies to facilitate discussions between modellers and regulators of chemical risk assessment. Proof-of-concepts of generic PBK modelling approaches are published in the scientific literature at an increasing rate. Working on the previously proposed steps is, therefore, needed to gain confidence in PBK modelling approaches for regulatory use.
Collapse
Affiliation(s)
| | - Ans Punt
- Wageningen Food Safety Research, Wageningen, The Netherlands
| | - John Wambaugh
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC USA
| | | | | | - Styliani Fragki
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | | | | | - Joost Westerhout
- The Netherlands Organisation for Applied Scientific Research TNO, Utrecht, The Netherlands
| | - Dennis Mueller
- Research and Development, Crop Science, Bayer AG, Monheim, Germany
| | - Hequn Li
- Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire UK
| | - Quan Shi
- Shell Global Solutions International B.V, The Hague, The Netherlands
| | - Timothy W. Gant
- School of Public Health, Faculty of Medicine, Imperial College London, London, UK
| | - Phil Botham
- Syngenta, Jealott’s Hill, Bracknell, Berkshire UK
| | - Rémi Bars
- Crop Science Division, Bayer S.A.S., Sophia Antipolis, France
| | - Aldert Piersma
- National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | | | - Nynke I. Kramer
- Toxicology Division, Wageningen University, PO Box 8000, 6700 EA Wageningen, The Netherlands
| |
Collapse
|
11
|
Liu X, Cheruvu HS, Anissimov YG, van der Hoek J, Tsakalozou E, Ni Z, Ghosh P, Grice JE, Roberts MS. Percutaneous absorption of steroids from finite doses: Predicting urinary excretion from in vitro skin permeation testing. Int J Pharm 2022; 625:122095. [PMID: 35961420 DOI: 10.1016/j.ijpharm.2022.122095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 08/01/2022] [Accepted: 08/05/2022] [Indexed: 10/15/2022]
Abstract
Pharmacokinetic (PK) models are widely used to describe drug permeation across the epidermal membrane barrier, the stratum corneum (SC). Here, we extend our previously reported diffusion and compartment-in-series models to describe plasma concentrations, urinary excretion-time profiles and exposure estimates after topically applied finite doses of solvent deposited solids. In vivo models were derived by convolution of a skin absorption input function for finite dosing with that for in vivo disposition PK. In vitro skin permeation test (IVPT) and in vivo urinary excretion data for cortisone, desoxycorticosterone, and testosterone were extracted from literature for model validation and establishment of in vitro - in vivo relationships (IVIVR). Both SC diffusion and SC 3-compartment-in-series PK models adequately described experimental in vitro and in vivo permeation data, with similar model parameter estimates for SC diffusion time and bioavailability. A satisfactory IVIVR was generated for cortisone, whereas testosterone and desoxycorticosterone showed higher bioavailability in vitro compared to in vivo. In recognising that future prospective studies need to both have an adequate sampling schedule and be harmonized for robust IVIVRs, we developed expressions for predicting extent of absorption and time for peak absorption for both in vitro and in vivo studies. Other study parameters, such as application site, applied dose, and application techniques, can also affect drug permeability through skin during dosage form metamorphosis after finite dose application, and a lack of correlation may result if these are poorly matched.
Collapse
Affiliation(s)
- Xin Liu
- Therapeutics Research Centre, University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia
| | - Hanumanth S Cheruvu
- Therapeutics Research Centre, University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia
| | - Yuri G Anissimov
- School of Environment and Science, Griffith University, Parklands Drive, Southport, QLD 4222, Australia
| | - John van der Hoek
- UniSA STEM, University of South Australia, Adelaide SA5011, Australia
| | - Eleftheria Tsakalozou
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - Zhanglin Ni
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - Priyanka Ghosh
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA
| | - Jeffrey E Grice
- Therapeutics Research Centre, University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.
| | - Michael S Roberts
- Therapeutics Research Centre, University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia; UniSA Clinical and Health Sciences, University of South Australia and Therapeutics Research Centre, Basil Hetzel Institute for Translational Medical Research, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
| |
Collapse
|
12
|
Zhang J, Yang Y, Ashraf M, Cruz CN, Lee S, Faustino PJ. An advanced automation platform coupled with mass spectrometry for investigating in vitro human skin permeation of UV filters and excipients in sunscreen products. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2022; 36:e9273. [PMID: 35178789 DOI: 10.1002/rcm.9273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/22/2021] [Accepted: 12/23/2021] [Indexed: 06/14/2023]
Abstract
RATIONALE Systemic absorption of UV-filtering chemicals following topical application of sunscreens may present a safety concern. The Food and Drug Administration (FDA) had recommended an in vitro skin permeation test (IVPT) to evaluate the potential of this safety risk for the evaluation of sunscreens prior to clinical studies. Therefore, a sensitive and robust bioanalytical method(s) were required for IVPT studies of different topical sunscreen products. METHODS An analytical procedure to quantitate sunscreen UV-filtering components and excipients in IVPT samples including avobenzone, octocrylene, oxybenzone, ecamsule, methylparaben and propylparaben was developed employing a RapidFire 360 robotic sample delivery system coupled with a triple quadrupole mass spectrometer. The analytical procedure was developed and validated according to the requirements of the FDA Bioanalytical Method Validation Guidance for Industry (2018). RESULTS The analytical method provided a turnaround time of 12 seconds per sample and was determined to be accurate, precise, specific, and linear over the corresponding analytical ranges. The validated method was successfully applied for two IVPT studies for evaluating the skin permeation potential of UV-filtering chemicals and assisting with the selection of the sunscreen products for the clinical study conducted by the FDA. CONCLUSIONS This work highlights the first analytical procedure that has applied a non-chromatographic-MS/MS automation platform to an in vitro biopharmaceutics study. The analytical platform simultaneously quantitated four UV filters and two excipients in complex media to evaluate their permeation in IVPT studies. The sample throughput and analytical performance of advanced automation platforms indicate their analytical procedure has the potential to significantly advance the efficiency of IVPT studies to evaluate permeation of a wide variety of UV chemical filters and excipients for topical OTC sunscreen products.
Collapse
Affiliation(s)
- Jinhui Zhang
- Division of Product Quality Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD, USA
| | - Yang Yang
- Division of Product Quality Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD, USA
| | - Muhammad Ashraf
- Division of Product Quality Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD, USA
| | - Celia N Cruz
- Division of Product Quality Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD, USA
| | - Sau Lee
- Office of Pharmaceutical Quality, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA
| | - Patrick J Faustino
- Division of Product Quality Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Silver Spring, MD, USA
| |
Collapse
|
13
|
Rapalli VK, Mahmood A, Waghule T, Gorantla S, Kumar Dubey S, Alexander A, Singhvi G. Revisiting techniques to evaluate drug permeation through skin. Expert Opin Drug Deliv 2021; 18:1829-1842. [PMID: 34826250 DOI: 10.1080/17425247.2021.2010702] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Investigating the transportation of a drug molecule through various layers of skin and determining the amount of drug retention in skin layers is of prime importance in transdermal and topical drug delivery. The information regarding drug permeation and retention in skin layers aids in optimizing a formulation and provides insight into the therapeutic efficacy of a formulation. AREAS COVERED This perspective covers various methods that have been explored to estimate drug/therapeutics in skin layers using in vitro, ex vivo, and in vivo conditions. In vitro methods such as diffusion techniques, ex vivo methods such as isolated perfused skin models and in vivo techniques including dermato-pharmacokinetics employing tape stripping, and microdialysis are discussed. Application of all techniques at various stages of formulation development where various local and systemic effects need to be considered. EXPERT OPINION The void in the existing methodologies necessitates improvement in the field of dermatologic research. Standardization of protocols, experimental setups, regulatory guidelines, and further research provides information to select an alternative for human skin to perform skin permeation experiments to increase the reliability of data generated through the available techniques. There is a need to utilize multiple techniques for appropriate dermato-pharmacokinetics evaluation and formulation's efficacy.
Collapse
Affiliation(s)
- Vamshi Krishna Rapalli
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India
| | - Arisha Mahmood
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India
| | - Tejashree Waghule
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India
| | - Srividya Gorantla
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India
| | - Sunil Kumar Dubey
- Medical Research, R&D Healthcare Division, Emami Ltd, Kolkata, India
| | - Amit Alexander
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, India
| | - Gautam Singhvi
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India
| |
Collapse
|
14
|
Lin B, Liu K, Qiu Y. Preparation of modified polysulfone material decorated by sulfonated citric chitosan for haemodialysis and its haemocompatibility. ROYAL SOCIETY OPEN SCIENCE 2021; 8:210462. [PMID: 34540249 PMCID: PMC8437023 DOI: 10.1098/rsos.210462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 07/12/2021] [Indexed: 05/18/2023]
Abstract
Polysulfone (PSF) works potentially in haemodialysis due to its great mechanical and chemical stability, but performs poorly in haemocompatibility. For promoting the unpleasant haemocompatibility, sulfonated citric chitosan (SCACS) with the structure and groups similar to heparin was primarily synthesized by acylation and sulfonation. Furthermore, the chloroacylated PSF was pretreated by electrophilic chloroacetyl chloride to achieve more active sites for further reaction; the following membranes underwent the amination and were named amination polysulfone (AMPSF) membranes. Moreover, SCACS with abundant carboxyl and sulfonic groups was covalently grafted at the surface of pretreated PSF membranes, called PSF-SCACS membranes. The PSF-SCACS membranes were successfully synthesized and characterized by 1H NMR, ATR-FTIR and XPS. In addition, the water contact angle of PSF-SCACS membranes decreased by 47° and the morphologies of the membranes changed little compared with the unmodified PSF membranes. The haemocompatible testing results, including protein adsorption, platelet adhesion, haemolysis rate, plasma recalcification time, activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT), demonstrated that the PSF-SCACS membranes possessed excellent haemocompatible performances, and SCACS played an important role in the modification.
Collapse
Affiliation(s)
- Bingxian Lin
- College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, People's Republic of China
| | - Kaiming Liu
- College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, People's Republic of China
| | - Yunren Qiu
- College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, People's Republic of China
| |
Collapse
|